NAME(S) |
ESTROGEN |
CONTENT
(µg) |
PROGESTIN
|
CONTENT
(µg) |
| Monophasic Pills
(per pill) |
| Eugynon, Ovral |
Ethinyl estradiol |
50 |
Norgestrel |
500 |
| Lo-Femenal (USAID),
Lo-Ovral |
Ethinyl estradiol |
30 |
Norgestrel |
300 |
| Alesse, Loette, Leios, Miranova |
Ethinyl estradiol |
20 |
Levonorgestrel |
150 |
| Microgynon,
Nordette, Levlen,
Ovranette |
Ethinyl estradiol |
30 |
Levonorgestrel |
150 |
| Neogynon |
Ethinyl estradiol |
50 |
Levonorgestrel |
250 |
| Loestrin 1/20, Minestril |
Ethinyl estradiol |
20 |
Norethindrone |
1,000 |
| Noriday (USAID), Ortho-Novum 1/50,
Norinyl 1/50 |
Mestranolb |
50 |
Norethindrone |
1,000 |
| Norminest (USAID), Brevicon,
Modicon |
Ethinyl estradiol |
35 |
Norethindrone |
500 |
| Norquest (USAID) |
Ethinyl estradiol |
35 |
Norethindrone |
1,000 |
| Desogen,
Ortho-Cept, Marvelon,
Novelon, (Mercilon 20 µg EE) |
Ethinyl estradiol |
35 |
Desogestrelc |
150 |
Ortho-Cyclen, Cilest
Effiprev |
Ethinyl estradiol |
35 |
Norgestimate |
250 |
Femodene, Femovan, Ginoden,
Gynara, Minulet
(30µg EE/50µg gestodene) |
Ethinyl estradiol |
30 |
Gestodenec |
75 |
| Triphasic
Pills (per pill) |
| Logynon,
Triphasil,
Tri-Levlen, Tri-Quilar 6 brown tablets
5 white tablets
10 yellow tablets |
Ethinyl estradiol Ethinyl
estradiol
Ethinyl estradiol |
30
40
30 |
Levonorgestrel Levonorgestrel
Levonorgestrel |
50
75
125 |
| Ortho-Novum 7/7/7 7 white tablets
7 light peach tablets
7 peach tablets |
Ethinyl estradiol Ethinyl
estradiol
Ethinyl estradiol |
35
35
35 |
Norethindrone Norethindrone
Norethindrone |
500
750
1,000 |
| Injectables
(per injection) |
| Cyclofem |
Estradiol cypionate |
5 mg |
DMPA |
25 mg |
| Mesigyna |
Estradiol valerate |
5 mg |
NET-EN |
50 mg |
aMost readily available monophasic
COCs contain 20–35 µg ethinyl estradiol (EE). "High-dose" COCs are those
containing 50 µg EE or more.
b50 µg mestranol has the biologic potency of 30–35 µg EE; therefore, it
should not be considered a high-dose COC.
cPreliminary
results suggest that users of COCs containing the new progestins desogestrel and gestodene
have a higher risk of venous blood clotting problems than those using COCs containing
leconorgestrel or norethindrone. WHO advises that until further information is available,
COCs containing progestins other than desogestrel and gestodene may be preferred. (No COCs
containing these new progestins are distributed by USAID.)
![[Previous Page]](../../6images/PG/blrprev.gif) ![[Next Page]](../../6images/PG/blrnext.gif) ![[TOC]](../../6images/PG/blrtoc.gif)
Go to PocketGuide for Family Planning Service Providers |
